Archive
1250 articles, sorted by publication time.
A research team used lanthanide ions to strengthen binding between cells and homologous extracellular vesicles, identifying rare tumor signals in a small set of triple-negative breast cancer samples. Although sensitivity was high, hurdles involving workflow, specificity, and large-scale validation must still be overcome before the approach can become a clinical test.
This experimental platelet-derived biologic containing multiple proteins will be tested for safety as a single epidural injection; with only 24 participants, the trial is limited in size, and it is not yet possible to determine whether the therapy can actually reduce pain.
AcroCyte will use its cell expansion platform to screen and mass-culture patients’ own kidney progenitor cells, progressively evaluating the feasibility of organoid therapy and bioartificial kidneys. The project has taken its first step on the manufacturing front, but efficacy, safety, and quality consistency still await answers from animal studies.
Lonvo-z significantly reduced hereditary angioedema attacks with a single infusion and has entered a rolling U.S. submission; beyond the striking six-month data, the long-term safety of permanent editing remains central to regulatory review.
A research team has rewritten how fluorescence lifetime microscopy data are represented, reconstructing molecular environments, immune cell interactions, and differences in tumor tissue under extremely low-light conditions. This may ease bottlenecks in speed and phototoxicity, but cross-instrument validation is still needed before routine clinical use.
A research team combined computational design with experimental screening to create a TCR-like antibody that recognizes the KRAS G12D peptide–HLA complex. Cell experiments showed that it can direct immune attacks, but eligibility is limited by HLA type, and human treatment remains some way off.
A single-tablet regimen combining islatravir and lenacapavir maintained viral suppression for 48 weeks in two switch-treatment trials and was noninferior to daily medication. However, the current evidence applies only to adults with stable disease, while long-term outcomes and regulatory review remain to be confirmed.
The new compound FR-027 targets the nuclear export protein through a different chemical mechanism, demonstrating efficacy in multiple mouse tumor models without the marked decreases in platelets, lymphocytes, or neutrophils commonly seen with comparator drugs; however, whether these advantages will carry over to humans still requires clinical validation.
The research team identified an efficiency bottleneck in transient delivery, enabling a single dose to achieve editing rates of 24.2% to 64.2% in the mouse liver and retina. Therapeutic signals were observed for cholesterol, hereditary liver disease, and eye lesions, but manufacturing, safety, and durability issues remain to be resolved before human treatment.
A research team combined a highly active factor IX with engineered albumin, producing higher and more sustained clotting function in mice; the design could reduce the viral vector dose required in the future, but its safety and efficacy in humans still await clinical validation.
Intravenously administered antimiR-23b entered the brain in a model of myotonic dystrophy type 1, increased MBNL proteins, corrected some abnormal RNA splicing, and reversed a change in exploratory activity. The findings offer clues for addressing central nervous system symptoms but cannot yet be regarded as evidence of efficacy in humans.
Published in Science, this AI agent can independently break down questions, access databases, and execute code. It approached expert performance in several tests, but validation, oversight, and experimental safety remain hurdles before it can become a trustworthy “virtual biologist.”